Home
Inbox
Search
View Abstract
Content
Session(s)
P1271 Prevalence and Characteristics of Patients with COPD and Low Peak Inspiratory Flow Rate Recruited in a Phase 3 Development Program for Revefenacin, a Nebulized Once-Daily Long-Acting Muscarinic Antagonist
Download
Send by Mail
View Handout
Home
Inbox
Search